Aktuellt
SENASTE
Redeye initiates coverage of MedCap, a serial acquirer of niche life science SMEs that has posted strong organic growth, acquired growth, and ROIC increases in recent years. We consider the company’s share to be roughly fairly valued at today’s level and believe it needs to scale its capacity to deploy capital at high returns.
LÄS MER
